Director Peter C. Farrell of ResMed Inc (NYSE:RMD) sold 2,000 shares of the company’s common stock on March 4, 2026, at a sale price of $260.22 per share, producing gross proceeds of $520,440. The transaction price exceeded the stocks then-current trading price of $255.32.
Following the sale, Farrell is recorded as directly holding 62,773 shares of ResMed. The disposition was carried out under a Rule 10b5-1 plan that the director established on August 12, 2025.
At the time of the trade, ResMed had a market capitalization of $37.19 billion. InvestingPro commentary noted that the company was trading below its InvestingPro Fair Value, indicating the share price may be undervalued relative to that benchmark.
InvestingPro also flagged two governance and capital-allocation items: management has been an active buyer of shares in the open market, and the company has increased its dividend for 14 consecutive years. For investors seeking deeper valuation and performance analysis, InvestingPro offers a Pro Research Report covering ResMed and more than 1,400 additional U.S. equities.
ResMed released its fiscal second-quarter 2026 results showing adjusted earnings per share of $2.81, beating the consensus analyst estimate of $2.73. Revenue for the quarter was $1.4 billion, in line with expectations.
Following the results, RBC Capital Markets raised its price target for ResMed to $314 from $311, citing robust double-digit revenue and earnings growth that slightly outpaced both RBC's and consensus estimates. KeyBanc Capital Markets also increased its target to $302 from $299, pointing to what it described as "largely positive" financial results. Needham kept a Hold rating on the stock, highlighting that organic revenue growth improved to 8% in the second quarter from 7% in the first quarter, breaking a three-quarter trend of decelerating organic growth.
Despite the earnings beat and the upward revisions to price targets, ResMed's shares experienced a modest decline of 0.51% in after-market trading on the news.
This report focuses on the disclosed insider sale and the company's quarterly financials and does not provide investment advice. Readers seeking further, in-depth research on ResMed's valuation and operating performance can consult the Pro Research Report referenced above.